Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors.
Industry sector: Medical
Sector classification: Surgical & medical instruments
Deep Learning based analysis and prediction model for Boston Scientific Corporation (BSX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for BSX model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
|% Held by Insiders||0.74%|
|% Held by Institutions||90.57%|
|EPS (last reported FY)||$1.11|
|EPS (last reported Q)||$0.31|
|EPS, estimated (last reported Q)||$0.31|
|Total revenues||$8 B|
|Net income||$0 B|